Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyse the changes of A-H premium on 154 stocks over the last week. The average A-H premium was 79.2% as of May 30th.</li>
<li>The average A-H premium changed by -1.3ppt week-on-week, led by health care, information technology, utilities and offset by consumer staples, materials.</li>
<li>We highlight weekly changes in A-H premium for Tigermed, Fosun Pharma, Cosco Shipping, CSSC O&amp;M Engineering, Joinn Lab, Livzon Pharmaceutical.</li>
</ul>


We analyse the changes of A-H premium on 154 stocks over the last week. The average A-H premium was 79.2% as of May 30th.
The average A-H premium changed by -1.3ppt week-on-week, led by health care, information technology, utilities and offset by consumer staples, materials.
We highlight weekly changes in A-H premium for Tigermed, Fosun Pharma, Cosco Shipping, CSSC O&amp;M Engineering, Joinn Lab, Livzon Pharmaceutical.


A-H Premium Weekly (May 30th): Tigermed, Fosun Pharma, Cosco Shipping, CSSC O&M Engineering

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Jiangsu Hengrui Pharmaceuticals / Equity Capital Markets

Jiangsu Hengrui Pharmaceuticals (1276 HK)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/jiangsu-hengrui-pharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:44224:1" rel="noopener">Jiangsu Hengrui Pharmaceuticals (1276 HK)</a> has launched its H Share listing at HK$41.45 to HK$44.05 per H Share. Pricing will be on 21 May.</li>
<li>I discussed the H Share listing in <a href="https://www.smartkarma.com/insights/jiangsu-hengrui-pharma-h-share-listing-the-investment-case" target="_blank" data-smartkarma-citation="insights:185190" rel="noopener">Jiangsu Hengrui Pharma H Share Listing: The Investment Case</a>. </li>
<li>The proposed AH discount can be argued as either light or attractive. I lean toward the latter and would participate in the H Share listing.</li>
</ul>



Jiangsu Hengrui Pharmaceuticals (1276 HK) has launched its H Share listing at HK$41.45 to HK$44.05 per H Share. Pricing will be on 21 May.
I discussed the H Share listing in Jiangsu Hengrui Pharma H Share Listing: The Investment Case. 
The proposed AH discount can be argued as either light or attractive. I lean toward the latter and would participate in the H Share listing.


Jiangsu Hengrui Pharma H Share Listing (1276 HK): Valuation Insights

Contemporary Amperex Technology (CATL) / Equity Capital Markets

Contemporary Amperex Technology (CATL) (300750 CH)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/contemporary-amperex-technolog" target="_blank" data-smartkarma-citation="entities:24404:1" rel="noopener">Contemporary Amperex Technology (CATL) (300750 CH)</a> has launched its H Share listing at a maximum price of HK$263. Pricing will be on 19 May, and the listing on 20 May.</li>
<li>I discussed the H Share listing in <a href="https://www.smartkarma.com/insights/catl-h-share-listing-the-investment-case" target="_blank" data-smartkarma-citation="insights:176396" rel="noopener">CATL H Share Listing: The Investment Case</a>, <a href="https://www.smartkarma.com/insights/catl-h-share-listing-ah-discount-views" target="_blank" data-smartkarma-citation="insights:184844" rel="noopener">CATL H Share Listing: AH Discount Views</a>, <a href="https://www.smartkarma.com/insights/catl-h-share-listing-phip-reinforces-the-investment-case" target="_blank" data-smartkarma-citation="insights:185326" rel="noopener">CATL H Share Listing: PHIP Reinforces the Investment Case</a>.</li>
<li>Our valuation analysis suggests that the low AH discount can be justified. We would participate in the listing.</li>
</ul>



Contemporary Amperex Technology (CATL) (300750 CH) has launched its H Share listing at a maximum price of HK$263. Pricing will be on 19 May, and the listing on 20 May.
I discussed the H Share listing in CATL H Share Listing: The Investment Case, CATL H Share Listing: AH Discount Views, CATL H Share Listing: PHIP Reinforces the Investment Case.
Our valuation analysis suggests that the low AH discount can be justified. We would participate in the listing.


CATL H Share Listing (3750 HK): Valuation Insights

<ul>
<li>
<a href="https://www.smartkarma.com/entities/contemporary-amperex-technolog" target="_blank" data-smartkarma-citation="entities:24404:1" rel="noopener">Contemporary Amperex Technology (CATL) (300750 CH)</a>, the world's largest supplier of EV and ESS batteries, is set to launch an H Share listing to raise US$5 billion.</li>
<li>In <a target="_blank" rel="noopener">CATL H Share Listing: The Investment Case</a>, a leading market position, forecasted return to growth, peer-leading profitability, cash generation, peer-leading FCF margin and an attractive valuation are highlighted.  </li>
<li>In this note, I examine the likely discount CATL will offer its H Shares compared to the A Shares.</li>
</ul>



Contemporary Amperex Technology (CATL) (300750 CH), the world's largest supplier of EV and ESS batteries, is set to launch an H Share listing to raise US$5 billion.
In CATL H Share Listing: The Investment Case, a leading market position, forecasted return to growth, peer-leading profitability, cash generation, peer-leading FCF margin and an attractive valuation are highlighted.  
In this note, I examine the likely discount CATL will offer its H Shares compared to the A Shares.


<ul>
<li>We analyse the changes of A-H premium on 150 stocks over the last week. The average A-H premium was 90.4% as of Apr 18th.</li>
<li>The average A-H premium changed by -0.5ppt week-on-week, led by health care, consumer staples, materials and offset by real estate, energy, consumer discretionary.</li>
<li>We highlight weekly changes in A-H premium for Remegen, Shandong Gold Mining, Innocare Pharma, China Oilfield Services.</li>
</ul>


We analyse the changes of A-H premium on 150 stocks over the last week. The average A-H premium was 90.4% as of Apr 18th.
The average A-H premium changed by -0.5ppt week-on-week, led by health care, consumer staples, materials and offset by real estate, energy, consumer discretionary.
We highlight weekly changes in A-H premium for Remegen, Shandong Gold Mining, Innocare Pharma, China Oilfield Services.


A-H Premium Weekly (Apr 18th): Remegen, Shandong Gold Mining, Innocare Pharma

China

JL MAG Rare-Earth Co., Ltd. manufactures rare earth materials. The Company produces NdFeB magnet materials and other rare earth products. JL MAG Rare-Earth supplies its products to wind power, new energy vehicles, inverter air conditioners, energy saving elevators, and other fields.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

JL Mag Rare-Earth (300748 CH)

A-H Premium Weekly (May 30th): Tigermed, Fosun Pharma, Cosco Shipping, CSSC O&M Engineering

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Tigermed, Fosun Pharma, Cosco Shipping, CSSC O&M...

Ke Yan, CFA, FRM

A-H Premium Weekly (Apr 18th): Remegen, Shandong Gold Mining, Innocare Pharma

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Remegen, Shandong Gold Mining, Innocare Pharma, China...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

A-H Premium Weekly (May 30th): Tigermed, Fosun Pharma, Cosco Shipping, CSSC O&M Engineering

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Tigermed, Fosun Pharma, Cosco Shipping, CSSC O&M...

Ke Yan, CFA, FRM

Jiangsu Hengrui Pharma H Share Listing (1276 HK): Valuation Insights

The proposed AH discount can be argued as either light or attractive. I lean toward the latter and would participate in the H Share listing.

Arun George

CATL H Share Listing (3750 HK): Valuation Insights

At the maximum offer price, the gross proceeds are US$4.0 billion. Our valuation analysis suggests that the low AH discount can be justified. We...

Arun George

CATL H Share Listing: AH Discount Views

CATL is potentially launching an H Share listing on Tuesday to raise US$5 billion. In this note, I examine the likely discount CATL will offer its...

Arun George

A-H Premium Weekly (Apr 18th): Remegen, Shandong Gold Mining, Innocare Pharma

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Remegen, Shandong Gold Mining, Innocare Pharma, China...

Ke Yan, CFA, FRM